NIHR
to provide early advice on study design, clinical pathway analysis, human factors, usability, patient engagement and health economic analysis. The UK has a large and diverse population cared
for in a single healthcare system with rich health data. NIHR supports life science companies to identify patients to inform and participate in research, as well as to find and access datasets. The NIHR also offers companies dedicated
support to plan, place and deliver their studies, including feasibility assessments, effective study start-up and delivery. This also includes the ability to execute novel trial designs and digital recruitment approaches, and to ‘decentralise’ elements of a study where possible to improve recruitment and retention. Companies interested in capitalising on all that the UK and NIHR has to offer can work with the NIHR’s Industry team to navigate the UK and NHS ecosystem. Danish SME, UNEEG Medical, who want to
revolutionise epilepsy management, has taken advantage of NIHR’s support. NIHR assisted with trial design and recruitment, provided expertise on clinical evaluation, health economic analysis and site identification for the REAL-ASE trial. This real word evidence trial across NHS sites will enable UK market access.
“The support the NIHR provided will help us
generate evidence in an NHS setting which will further support the published NICE Advice guidance of the 24/7 EEG SubQ for epilepsy”. Chris Young, Sales & Market Development Director, UNEEG Medical. The NIHR can support your company to generate
the required evidence to progress your HealthTech products towards the market.
For a more in-depth discussion about the NIHR’s expertise in HealthTech, talk to the NIHR Industry team. To find out more, visit the NIHR website or scan:
SIMULATION THEATRE SUPPORTER
DUB AI 2025
UKHEALT HCAREPA VILION. COM
17
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
